Journal of Hypertension · 1988 · 17 citations · 0 references
MedicinePharmacokineticsPharmacologyAnesthesiaGeneral AnesthesiaPerioperative PharmacologyBlood-brain Barrier DeliveryBlood-brain Barrier PenetrationBlood-brain Barrier PharmacologyIntracranial HypertensionIntracranial PressureIntracranial Pressure Monitoring5-Hydroxytryptamine Receptor PharmacologyBlood-brain Barrier PermeabilityCerebral Drug PenetrationIncreased Intracranial PressureIntracranial Pressure DynamicsIntravenous Bolus InjectionPharmacokinetics At The Blood-brain BarrierSystolic Blood Pressure
We studied eight patients undergoing craniotomy for intracerebral tumour surgery requiring monitoring of intracranial pressure. All these patients showed significantly increased systolic arterial pressure, during anaesthesia. Following an average dose of 0.8 +/- 0.22 mg/kg urapidil, systolic arterial pressure returned to baseline values without a significant change in intracranial pressure. In nine patients, urapidil concentrations in plasma and cerebrospinal fluid were assayed following an intravenous injection of urapidil. Urapidil was found in the cerebrospinal fluid in concentrations between 5 and 99 ng/ml after total cumulative bolus injections of 10-75 mg. There is evidence that in clinically applied doses urapidil permeates the blood-brain barrier and reaches cerebrospinal fluid concentrations that allow an interaction with central 5-hydroxytryptamine-1A receptors.